Yahoo Finance • 6 days ago
Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief Financial Officer COPENHAGEN, Denmark, J... Full story
Yahoo Finance • 10 days ago
European equities traded in the US as American depositary receipts were tracking higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 12 days ago
(RTTNews) - Evaxion Biotech A/S (EVAX) announced the expansion of its vaccine pipeline with the addition of EVX-B4, a novel vaccine candidate targeting Group A Streptococcus or GAS. This new program is powered by the company's proprietary... Full story
Yahoo Finance • 12 days ago
COPENHAGEN - Biotech company Evaxion A/S (NASDAQ:EVAX), currently valued at $15.5 million and showing strong momentum with a 13% gain last week, announced on Wednesday it has initiated development of a preventive vaccine against Group A St... Full story
Yahoo Finance • 12 days ago
Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combatGroup A Streptococcus (GAS)New vaccine program is added to Evaxion’s pipeline under the name EVX-B4Urgent need f... Full story
Yahoo Finance • 14 days ago
European equities traded in the US as American depositary receipts were softer late Monday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 20 days ago
European equities traded in the US as American depositary receipts were tracking lower late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • last month
Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens t... Full story
Yahoo Finance • last month
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial re... Full story
Yahoo Finance • last month
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 finan... Full story
Yahoo Finance • 2 months ago
Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data packageWill provide insights into the durability of immune and clinical... Full story
Yahoo Finance • 3 months ago
Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vacci... Full story
Yahoo Finance • 3 months ago
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financi... Full story
Yahoo Finance • 3 months ago
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024... Full story
Yahoo Finance • 3 months ago
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EV... Full story
Yahoo Finance • 4 months ago
Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment... Full story
Yahoo Finance • 5 months ago
Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders’ equity requirement Evaxion has restored its equity above the minimum requirement through capital market activitiesEvaxion’s... Full story
Yahoo Finance • 5 months ago
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an agg... Full story
Yahoo Finance • 5 months ago
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an agg... Full story
Yahoo Finance • 5 months ago
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its equity above the minimum requirement thro... Full story